Zalifrelimab, Evofosfamide, Balstilimab
Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Head And Neck Squamous Cell Carcinoma
Phase I/II
Recruiting
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Jan 09, 2025
―
Gemcitabine, Nab-paclitaxel, Botensilimab
Metastatic Pancreatic Ductal Adenocarcinoma
Phase II
Active Not Recruiting
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Nov 18, 2022
―
Standard of Care, Botensilimab, Balstilimab
Metastatic Colorectal Cancer
Phase II
Active Not Recruiting
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Nov 01, 2022
―
Botensilimab, Balstilimab
Advanced Melanoma
Phase II
Active Not Recruiting
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Sep 02, 2022
―
Botensilimab, Balstilimab, Agen1571
Advanced Solid Tumor
Phase I
Completed
Study of AGEN1571 in Participants With Advanced Solid Tumors
May 12, 2022
―
Agen2034, Cr6086
Solid Tumor, Gastric Cancer, Refractory Metastatic Colorectal Cancer, Metastatic Microsatellite-Stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic Gi Cancers
Phase I/II
Recruiting
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Jan 20, 2022
―
Agen1777, A Pd-1 Inhibitor
Advanced Cancer
Phase I
Completed
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Aug 10, 2021
―
Gemcitabine, Nab Paclitaxel, Nlm-001, Zalifrelimab
Pancreatic Ductal Adenocarcinoma
Phase I/II
Active Not Recruiting
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
Mar 30, 2021
―
Botensilimab, Agen2373
Advanced Cancer
Phase I
Completed
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Oct 02, 2019
―
Agen2034, Agen1884
Cervical Cancer
Phase II
Active Not Recruiting
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Mar 19, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Agenus (AJ8) have in its pipeline
AJ8 is currently developing the following drugs: Zalifrelimab, Evofosfamide, Balstilimab, Gemcitabine, Nab-paclitaxel, Botensilimab, Standard of Care, Botensilimab, Balstilimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.